What the researchers examined
A study published on October 20, 2026, in the Journal of General Internal Medicine examined prescribing patterns in 3,246 community-dwelling adults aged 65 or older who already had dementia. Using data from 2010–2022, researchers studied patterns before and after the March 2016 CDC opioid prescribing guideline.
Gabapentinoid prescribing rose from 9.5% to 11.5% over the study period. The analysis did not identify a change in that prescribing trend following the guideline. Its gabapentinoid category included both gabapentin and pregabalin; these are different medicines.
What the findings do not establish
This was a prescribing-pattern study in people with existing dementia, not a test of whether either drug causes new dementia. The authors said the impact of the prescribing shifts on symptom control remains unknown. It does not establish legal eligibility or an individual cause of injury.
Why the medication timeline matters
For a family considering a legal review, distinguish symptoms that began before treatment from symptoms first noticed afterward. Keep the dates of diagnosis and treatment separately. A medication prescribed after a dementia diagnosis cannot explain the original onset simply because both appear in the same medical chart.
Ask the pharmacy for a dispensing history and preserve clinician notes describing why treatment began. Do not guess missing dates; mark them as approximate. See our records checklist and guide to the wider cognitive research.
Timing note: This publication predates our October 25 site update. It is included here as additional research context, not as a newly issued safety warning. Do not change prescribed treatment without your clinician’s advice.
